Biotech Startups

OtoImmune is developing precision immunology products under its mOI and mOI Health brands. The page provides no further detail about the specific products, technology, or target customers.

1 investor

Otologic Pharmaceutics (OPI) is a pharmaceutical company developing treatments for acute and chronic hearing loss to reduce permanent hearing disorders. Its pipeline includes an oral drug for noise-induced hearing loss and a therapy aimed at regenerating sensory hair cells.

1 investor

Ourobio develops engineered microorganisms that convert industrial byproducts into biomaterials using synthetic biology. The company targets industries seeking sustainable alternatives to petroleum-derived chemicals and materials.

1 investor

Outdefine provides a governed decisioning and execution layer for clinical trial teams, using trial-trained AI inference and workflow agents to support site feasibility ranking, study risk monitoring, and real-world evidence analysis. It sits above existing clinical systems to connect trial data, protocol rules, and outcomes for pharmaceutical and life sciences operations.

1 investor

Outlook Therapeutics develops ophthalmic therapies for retinal diseases, including anti-VEGF treatments for conditions such as neovascular (wet) age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion. Its lead product, LYTENAVA (bevacizumab-vikg), is an FDA-approved ophthalmic bevacizumab formulation for adults with wet AMD.

1 investor

Overseed is a French company developing medical cannabis treatments, from plant cultivation to finished medicines, to address patient pain, anxiety, and spasticity. It works on pharmaceutical-grade formulations such as oral oils, inhalables, and sublingual sprays, in partnership with the CNRS and university hospitals, for the French regulated medical cannabis market.

1 investor

Overture develops precision antibody therapeutics for obesity treatment, targeting metabolic dysfunction pathways to reduce fat mass while preserving lean muscle through monthly-dosed therapeutic approaches.

1 investor

Benchling In Vivo is software for managing preclinical in vivo studies, including study design, animal randomization, data capture, and reporting across efficacy, tolerability, and survival studies. The platform consolidates animal assignment, dosing schedules, and study observations in a digital system to replace spreadsheets and paper records.

1 investor

OVO Biomanufacturing offers a cloud-based software platform that helps viral vaccine manufacturers manage and reduce defective interfering particles (DIPs) to improve production yields. Using Next Generation Sequencing data, the platform guides producers to optimise DIP populations when creating working seed stocks for live attenuated and inactivated viral vaccines, with an initial focus on the influenza vaccine market.

1 investor

Ownmed Innovation is a spin-off that develops medical devices and technologies to address unmet clinical needs, taking products through preclinical studies, clinical trials, and CE certification under EU regulation 2017/745. Its focus includes ostomy care, with a device aimed at restoring continence.

1 investor

OWP Pharmaceuticals is a privately held, commercial-stage neuroscience specialty pharmaceutical company that develops and markets branded generic and generic lamotrigine Starter Kits (Subvenite) for epilepsy and bipolar disorder in the U.S. Operating as a social enterprise, it donates profits to the ROW Foundation to support treatment of neurological disorders in under-resourced regions.

1 investor

Low-cost, AI-enabled platform that detects multiple microorganisms or contaminants in a single test and provides a fast antibiogram for antibiotic resistance.

1 investor

Oxford BioDynamics develops precision clinical diagnostic blood tests for detecting cancer and predicting treatment response in cancer patients, using its proprietary 3D genomic biomarker platform. The company serves oncologists and patients in the United States and internationally through its commercially available tests and partnerships with major pharmaceutical companies and research institutions.

1 investor

Oxurion is a French specialist in clinical biometrics and data management, providing the core technology for the Oxurion platform.

1 investor

OzoneBio is a Canadian green chemistry company that converts wood waste and lignocellulosic residues such as nutshells, bark, and lignin-rich biomass into bio-adipic acid and bio-based Nylon 66. Its materials target automotive, robotics, engineering, and fashion industries as lower-carbon alternatives to fossil-based nylon.

1 investor

OzoneBio engineers biologically-powered materials to replace fossil-based chemical production processes for industrial applications. The company targets the chemical manufacturing industry with sustainable alternatives designed for performance and environmental responsibility.

1 investor

OzStar Therapeutics is an Australian pharmaceutical company that develops a prebiotic derived from inulin as an adjunct for people with type 2 diabetes taking sulphonylurea medications. Its product is supplied as a Food for Special Medical Purpose and is ordered through healthcare professionals.

1 investor

P95 is a clinical research and pharmaceutical services company that supports pharmaceutical development through medical monitoring, epidemiology, biostatistics, study management, pharmacovigilance, and medical writing services.

1 investor

P-Mind develops non-invasive therapeutic technologies based on decades of research into magnetic fields and their interaction with living organisms, with a focus on treating pain disorders, neurological diseases, and cancer. The company manufactures and sells medical devices, including the alternating magnetic field therapy device "Eight" (エイト).

1 investor

P3 Therapeutics is developing a new class of anti-inflammatory small chemical molecules and works with partners on a humanized gut-entheseal organ-on-chip platform to study their mechanism of action, pharmacokinetics, pharmacodynamics, and biomarkers. The work is part of an application to the EUROSTARS 3 program under the TRIGG3R project.

1 investor

Pacific Biosciences manufactures consumables and reagent kits for long-read DNA and RNA sequencing platforms, serving genomics research and diagnostics labs.

1 investor

1 investor

Pace provides laboratory testing services to help customers assess environmental safety and health risks. Founded in 1978, the company serves organizations needing accurate testing and is committed to sustainable practices and regulatory compliance.

1 investor

Pacify Medical develops biomedical devices for wound management, specifically surgical and trauma wound care. The company's flagship product is a patent-protected skin spray device designed to improve wound healing outcomes.

1 investor